{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:42:14Z","timestamp":1784040134169,"version":"3.55.0"},"reference-count":31,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> To characterize treatment patterns and real-world clinical outcomes of patients with metastatic non\u2013small cell lung cancer (mNSCLC) who developed progression on an anti\u2013PD-1\/anti\u2013PD-L1, herein referred to as anti\u2013PD-(L)1, and platinum-doublet chemotherapy. <\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p> Eligible oncologists\/pulmonologists in the United States, Europe (France, Germany, and United Kingdom), and Japan completed electronic case report forms for patients with mNSCLC (no evidence of EGFR\/ALK\/ROS1 alterations). Eligible patients had disease progression on\/after an anti\u2013PD-(L)1 and platinum-doublet chemotherapy (received concurrently or sequentially), initiated a subsequent line of therapy (LOT) between 2017 and 2021, and had an Eastern Cooperative Oncology Group (ECOG) performance status 0-2 at this subsequent LOT initiation (index date). Overall survival (OS), time to treatment discontinuation (TTD), and real-world progression-free survival (rwPFS) after index were assessed using Kaplan-Meier analysis. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> Overall, 160 physicians (academic, 54.4%; community, 45.6%) provided deidentified data from 487 patient charts (United States, 141; Europe, 218; Japan, 128; at mNSCLC diagnosis: median age 66 years, 64.7% male, 81.3% nonsquamous, 86.2% de novo mNSCLC; at line of interest initiation: 86.0% ECOG 0-1, 39.6% liver metastases, 18.9% brain metastases, 79.1% smoking history). The most common treatment regimens upon progression after anti\u2013PD-(L)1\/platinum-doublet chemotherapy were nonplatinum chemotherapy (50.5%), nonplatinum chemotherapy plus vascular endothelial growth factor receptor inhibitor (12.9%), and platinum-doublet chemotherapy (6.6%). Median OS was 8.8 months (squamous, 7.8 months; nonsquamous, 9.5 months). Median TTD was 4.3 months (squamous, 4.1 months; nonsquamous, 4.3 months). Median rwPFS was 5.1 months (squamous, 4.6 months; nonsquamous, 5.4 months). <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> In this multiregional, real-world analysis of pooled patient chart data, patients with mNSCLC who had disease progression after anti\u2013PD-(L)1\/platinum-doublet chemotherapy had poor clinical outcomes with various treatment regimens, demonstrating an unmet clinical need for effective options after failure on anti\u2013PD-(L)1 and platinum-doublet chemotherapy treatments. <\/jats:p><\/jats:sec>","DOI":"10.1200\/go.23.00483","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T19:59:32Z","timestamp":1710446372000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":10,"title":["Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non\u2013Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3735-9063","authenticated-orcid":true,"given":"Ticiana A.","family":"Leal","sequence":"first","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anandaroop","family":"Dasgupta","sequence":"additional","affiliation":[{"name":"Eisai Inc, Nutley, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8565-9220","authenticated-orcid":true,"given":"Dominick","family":"Latremouille-Viau","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5801-6927","authenticated-orcid":true,"given":"Carmine","family":"Rossi","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7428-7273","authenticated-orcid":true,"given":"Pragya","family":"Rai","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc, Rahway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[{"name":"Paris Saclay University & Gustave Roussy Institute, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4852-3914","authenticated-orcid":true,"given":"Stephen V.","family":"Liu","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.009"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-019-01431-z"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00825"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0602"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.04.008"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00441"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.999343"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88453-8"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03022"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.04.009"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60845-X"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70586-2"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00912"},{"key":"b15","volume-title":"Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study","author":"ClinicalTrials.gov","year":"2023"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.006"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.061"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81666-x"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.04.004"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282020"},{"key":"b21","first-page":"728","volume":"4","author":"Yu X","year":"2021","journal-title":"Cancer Drug Resist"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1578"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.02.023"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.02.002"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.01.025"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.312"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1799"},{"key":"b31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0471"},{"key":"b32","volume-title":"CYRAMZA (Ramcirumab) Highlights of Prescribing Information","author":"Eli Lilly and Company","year":"2022"},{"key":"b33","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz060"},{"key":"b34","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30010059"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO.23.00483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T20:00:03Z","timestamp":1710446403000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO.23.00483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1200\/GO.23.00483"],"URL":"https:\/\/doi.org\/10.1200\/go.23.00483","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"2023-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2300483"}}